ArticleMolecular plant pathology2026
Molecular Mechanism Underlying Resistance Variation to the Novel Agrochemical Quinofumelin in Fusarium graminearum.
Article in Molecular plant pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Quinofumelin, a quinoline-based fungicide, demonstrated potent antifungal activity against Fusarium graminearum, the pathogen responsible for Fusarium head blight (FHB) in wheat. Previously, we elucidated that quinofumelin targets dihydroorotate dehydrogenase (DHODH), an indispensable enzyme in the de novo pyrimidine biosynthesis pathway. To explore its resistance mechanism, five FgDHODHII site-directed mutants with distinct genotypes were generated using the homologous recombination strategy. Sensitivity assays identified varying resistance levels: FgDHODHII-A94V remained sensitive to quinofumelin, FgDHODHII-D155T conferred low-level resistance, FgDHODHII-N281A conferred moderate-level resistance, and FgDHODHII-V179E/V179D conferred high-level resistance. Quinofumelin inhibition was reversed by the addition of uridine monophosphate (UMP), uridine or uracil. Although the mutants did not exhibit growth defects, quinofumelin-resistant mutants displayed reduced sporulation and virulence. Quinofumelin showed cross-resistance to ipflufenoquin, but no cross-resistance to other common fungicides (phenamacril, carbendazim, tebuconazole, pydiflumetofen, prothioconazole, fluopyram, benzovindiflupyr, pyraclostrobin and azoxystrobin). Molecular docking, molecular dynamics (MD) simulations and microscale thermophoresis (MST) revealed that D155T, V179E, V179D and N281A mutations altered the binding mode of quinofumelin, resulting in diminished binding affinity. This study provides key insights into its mode of action and resistance mechanism of quinofumelin, facilitating its application in sustainable FHB management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.